Building Saskatchewan
In April 2025, Dr. Goodenowe announced a $100 million investment to build health research, manufacturing, and community infrastructure in Moose Jaw, Saskatchewan, the city where his family has lived for six generations.
The location
Why Moose Jaw
Dr. Goodenowe's family has lived in the Moose Jaw region for six generations. His great-grandfather settled south of the city in 1909, and members of the family have farmed and built in the area continuously since. The decision to base the project in Moose Jaw rather than in a larger research centre is, by Dr. Goodenowe's own account, rooted in that family history.
Moose Jaw is a city of approximately 34,000 in southern Saskatchewan. It does not host an existing health research hub of the kind typically associated with the type of infrastructure being built. The project is therefore being constructed largely from the ground up, with research-grade equipment, manufacturing capacity, and clinical operations being assembled in the same community.
Infrastructure
What is being built
The project comprises five facilities in Moose Jaw, research-grade analytical and imaging instrumentation, manufacturing capacity, and a drug development program. Three facilities are open and two are under construction.
Chemistry and Manufacturing Facility
Under construction at 30 Mackenzie Lane. A facility of more than 10,000 square feet designed to produce plasmalogen precursors and advanced nutrition products for domestic distribution and international export.
Advanced health technologies
The facilities will house advanced technologies for measuring and improving health and quality of life of a kind most communities of this size would not typically have access to. These include advanced biochemical monitoring, 3T functional MRI, cardiac imaging and ultrasound, photobiomodulation, ECG, EEG, and advanced vision and hearing assessment.
Drug development through DGDT
Through Dr. Goodenowe Dietary Therapeutics LLC (DGDT), Dr. Goodenowe is advancing ProdromeNeuro™, an alkyl-diacylglycerol plasmalogen precursor that he invented and synthesized in 2019, through FDA-regulated pathways for the investigation of Alzheimer's disease and related neurological conditions. ProdromeNeuro™ is investigational and has not been approved by the FDA or any other regulatory authority as safe or effective for any indication. DGDT's multi-site clinical trial infrastructure is being built across Temecula, California, and Moose Jaw, Saskatchewan.
Five facilities in Moose Jaw
Three open: the Community Health Information Centre, Engage Café, and the 18,000 sq ft Restorative Health Centre at 1350 Lakeview Road. Two under construction: the Chemistry and Manufacturing Facility at 30 Mackenzie Lane, and the 15,000 sq ft Community Health Centre at 1400 Lakeview Road.
Economic impact
Jobs, infrastructure, and a long-term commitment
As of April 2025, more than 50 people are employed locally in Moose Jaw through the project. Five facilities have been acquired and are in various stages of construction and operation. The manufacturing facility under construction at 30 Mackenzie Lane is designed to produce for both domestic and international markets.
The total investment announced in April 2025 is $100 million.
Recognition
ABEX Award finalist
The Dr. Goodenowe Restorative Health Centre, operating under the legal name Lakeview Wellness Centre, has been named a finalist for two Saskatchewan Chamber of Commerce ABEX Awards: New Business Venture and Business Innovation. The ABEX Awards are awarded annually by the Saskatchewan Chamber of Commerce in recognition of business achievement across the province.